SCHEDULE 13G/A: Deep Track Capital Discloses 5.04% Stake in Olema Pharmaceuticals

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.04% in Olema Pharmaceuticals, Inc., totaling 3,442,833 shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 3,442,833 shares of Olema Pharmaceuticals, Inc. Common Stock.
• This ownership represents 5.04% of Olema Pharmaceuticals' outstanding Common Stock.
• The reporting persons share both voting and dispositive power over all 3,442,833 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported beneficial ownership.
• The percentage of class was calculated based on 68,333,065 Common Stock outstanding as of March 13, 2025, as reported in Olema Pharmaceuticals' Form 10-K filed on March 18, 2025.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing indicates a significant investment stake by a specialized biotechnology fund in Olema Pharmaceuticals, a company operating in the biotechnology sector. Such disclosures are common for institutional investors accumulating positions in public companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (over 5%) by Deep Track Capital may be viewed positively by some investors as a vote of confidence, potentially influencing market perception and trading activity.

Key Dates

Keywords

Olema Pharmaceuticals, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology